News

Parkinson’s patients carrying two types of genetic polymorphisms — a gene that has more than one variant in a given population — in the dopamine transporter gene are less likely to suffer from involuntary muscle movements associated with levodopa therapy, a study shows. The study, “DAT gene polymorphisms (rs28363170, rs393795)…

A better understanding of how Parkinson’s disease affects the laryngopharyngeal muscles of the esophagus could help identify those patients at risk for obstructive sleep apnea, according to a new study. The research, “Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinson’s disease,” was published in the journal Sleep and…

Deep brain stimulation can effectively reduce physical impairment caused by Parkinson’s disease and meets most patients’ expectations for improvements in several domains, a study reports. However, researchers found that the procedure did fall short of meeting most patients’ expectations concerning the reduction of non-motor symptoms. The study, “…

Women and Hispanic patients with Parkinson’s disease, as well as those living in Southern and Midwestern U.S. states, are most often prescribed inappropriate dementia therapies, a nationwide study reveals. The study, “Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease,” appeared…

Specific motor symptoms in Parkinson’s disease have a corresponding cognitive profile, with the tremor-dominant type being associated with less severe cognitive decline, a study reports. The study, “Cognitive decline in Parkinson’s disease: the impact of the motor phenotype on cognition,” was published in the Journal of Neurology,…

A protein called scarlet can protect nerve cells from the damaging effects of toxic alpha-synuclein aggregates that occur in Parkinson’s disease, according to results of research into a fruit fly model. The study, “Neurodegeneration and locomotor dysfunction in Drosophila scarlet mutants,” was published in the Journal…

Levels of brain-derived neurotrophic factor (BDNF) — a protein important in promoting the survival of dopaminergic neurons — are abnormally low in patients with Parkinson’s disease, regardless of whether these patients also have depression, a common non-motor symptom associated with the disease, a systematic review study reveals. The…

One in two women and one in three men older than 45 will develop Parkinson’s disease, dementia or stroke during their lifetime, a new study suggests. Preventive strategies to delay disease onset can reduce this risk by up to half. The study with those findings, “Lifetime risk of common neurological…

PhotoPharmics’s Spectramax light therapy reduces disease severity, lessens non-motor symptoms, and improves the quality of life of Parkinson’s patients, according to recent results of a controlled clinical study. The study,“Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic…

CENTOGENE and Denali Therapeutics are teaming up to identify and recruit Parkinson’s disease patients who carry mutations in the LRRK2 gene for future clinical trials, the companies announced. CENTOGENE will carry out a targeted global recruitment campaign to identify and characterize Parkinson’s patients with LRRK2…